In a 48-week clinical trial, higher doses consistently led to greater average weight loss: Weight loss by dose (48-week clinical trial) In this trial, at the highest dose (12 mg), people lost an average 24% of their starting weight on average
Tirzepatide is the first dual agonist which has been approved for chronic weight management, but numerous other dual and/or triple agonists (cagrisema, retatrutide, mazdutide and survodutide) are also in phase 3 trials as potential treatments for obesity and its metabolic complications
Januar 2024, abgerufen am 15
Weight Loss: Therapeutic Duplication Warnings for Vyvanse and Wegovy The concurrent use of Vyvanse and Wegovy raises important considerations regarding therapeutic duplication warnings , particularly due to their differing indications and mechanisms of action
(3) outcomes: all clinical outcomes, such as cardiovascular event, death, changing in glycosylated hemoglobin type A1C (HbA1c), body weight, fasting plasma glucose (FPG) and safety outcomes
